BioNTech SE (22UAy.DE) (Q1FY23)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.
The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors.
In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors.
The company also develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A.
BioNTech’s experienced 85% decline in earnings compared to the previous year. Company’s COVID-19 vaccine remains their sole commercial product. Sales reached a peak of €7.05bn in Q3FY21 but have since decelerated substantially. BioNTech has reaffirmed COVID-19 vaccine sales forecast for the year, expecting ~€5.51bn in total sales.
BioNTech’s stock price showed a downward trend in past 3-months. The stock declined by 13.7% during the period. The stock price declined by 34.89% in past 1-year. The stock has a 52-week high of €186.70 and its 52-week low is €91.62.
In the past 3 years, the stock has given ~120%. BNTX has a 50-day moving Avg. and 200-day moving Avg. of €99.62 and €127.77, respectively.
This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.
– Enterprise Value
– CrispIdea Forecast
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum
Actual & Historical Performance
– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Segment Performance
– Key Developments
– Price Performance
Stock Price Performance
No of Pages : 28
To download the previous quarter’s equity report CLICK HERE
To Download other equity/ stock report CLICK HERE
Follow our LinkedIn page for more updates